[333 Pages Report] The global inhalation and nasal spray generic drugs market is projected to have a moderate-paced CAGR of 8.96% during the forecast period. The current valuation of the inhalation and nasal spray generic drugs market is US$ 20.78 Billion in 2023. The value of the inhalation and nasal spray generic drugs market is anticipated to reach a high of US$ 49.01 by the year 2033.
This growth in the sales of inhalation and nasal spray generic drugs is supported by the following:
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Due to the rising incidence of asthma attacks in both children and adults, the asthma subsegment is projected to account for over 40.0% of total revenues in 2021. Approximately 10.3 million US residents, including children and adults under the age of 18, experienced asthma attacks in 2020, accounting for 41% of all incidents, as reported by the CDC's National Health Interview Survey. Additionally, the number of asthma-related visits to emergency rooms rose by approximately 57% in 2019.
New product introductions and increasing demand for generics in the treatment of chronic obstructive pulmonary disease (COPD) should drive growth in the inhalation and nasal spray generic drugs market sector over the forecast period. One such example is the generic version of Advair Diskus, WixelaInhub, which was approved by the FDA in January 2019 (manufactured by Mylan N.V.). It is used to treat chronic obstructive pulmonary disease and asthma. The expansion of the demand for inhalation and nasal spray generic drugs is anticipated to be boosted by these kinds of approvals.
| Attributes | Details |
|---|---|
| Market Value (2023) | US$ 20.78 Billion |
| Market Value (2033) | US$ 49.01 Billion |
| CAGR | 8.96% |
Rising Prevalence of Asthma and Chronic Obstructive Pulmonary Disease
Health issues like asthma and COPD are taken very seriously. A sizable fraction of the world's population is impacted by them. Asthma and chronic obstructive pulmonary disease (COPD) share several risk factors, including smoking, cigarette use, and environmental pollution. The American Lung Association reports that smoking is the leading cause of COPD and accounts for around 80% of COPD-related fatalities.
Over 360 and 175 million individuals suffered from asthma and COPD in 2015, respectively, according to the Global Burden of Disease Study. Asthma and chronic obstructive pulmonary disease are becoming more common as a result of the improved living standards seen in industrialized nations. But in poorer nations, where air pollution and smoking are more common, these diseases are more common among the population.
Market growth for generic inhalers and nasal sprays is anticipated to be bolstered by an aging population with chronic respiratory diseases, including COPD and asthma.
Market Growth of Generic Drugs May Be Stifled by Strict Regulations
As more and more low-price generic inhalation and nasal spray medications become available around the world, different regulatory authorities have opted for stringent criteria to focus on quality. Brazil, Mexico, and Russia are just a few of the emerging countries whose regulatory bodies have recently revised their policies on the sale of generic pharmaceuticals.
The sales of inhalation and nasal spray generic drugs in the global market have been significantly slowed as a result of the new regulatory standards.
Additionally, several pharmaceutical businesses operating in Russia are facing challenges due to the country's new regulatory legislation, which requires clinical trials for generic drugs. Similarly, the Drugs Controller General of India, the country's domestic drug regulatory organization, established several new drug advisory groups to monitor clinical studies, approve new drugs, etc.
Therefore, the demand for inhalation and nasal spray generic drugs is expected to grow slowly as a result of the tough and strict rules imposed by various developing countries.
Principal Consultant
Inhalation And Nasal Spray Generic Drugs Market:
| Differentiating Aspects | Inhalation And Nasal Spray Generic Drugs Market |
|---|---|
| CAGR | 8.96% |
| Market Valuation in 2023 | US$ 20.78 Billion |
| Projected Market Value in 2033 | US$ 49.01 Billion |
| Drivers |
|
Budesonide Inhaler Market:
| Differentiating Aspects | Budesonide Inhaler Market |
|---|---|
| CAGR | 6% |
| Market Valuation in 2023 | US$ 6,899.6 Million |
| Projected Market Value in 2033 | US$ 10,993.3 Million |
| Drivers |
|
Nasal Polyps Treatment Market:
| Differentiating Aspects | Nasal Polyps Treatment Market |
|---|---|
| CAGR | 6.9% |
| Market Valuation in 2023 | US$ 2,992.21 Billion |
| Projected Market Value in 2033 | US$ 5,088.90 Billion |
| Drivers |
|
With widespread use for the treatment of respiratory illnesses like asthma and COPD, bronchodilators are expected to represent over 25.0% of the market by 2021. Asthma and chronic obstructive pulmonary disease (COPD) are on the rise, which is also fueling. According to the World Health Organization (WHO), in 2019, there were over 262 million individuals living with asthma worldwide. The Asthma and Allergy Foundation of America estimates that by 2020, over 25 million people in the United States are likely to have asthma. As a result, the market is likely to be driven by the increasing demand for bronchodilators.
For the duration of the forecast, the market for combination pharmaceuticals is anticipated to grow at a compound annual rate of 9.85%. Combination medicine launched by major companies like Apotex Inc. and Teva Pharmaceutical Industries Ltd. is responsible for most of this expansion. When it comes to treating allergic rhinitis, for instance, Apotex Inc. introduced a generic version of Dymista (azelastine and fluticasone) nasal spray, originally developed by Meda Pharmaceuticals, in March 2020.
In 2021, retail pharmacies' share of total revenue was over 55.0% due to rising healthcare costs and robust sales of generic drugs. In the United States, for instance, generic medications accounted for almost 90% of prescriptions filled in 2019. Further, the average profit margin of generics in pharmacies is around 43%, indicating high income. The cost of pharmaceuticals has also risen steadily over time. Examples include a 4.9% increase in pharmaceutical spending in the United States between 2019 and 2020.
The sales of inhalation and nasal spray generic drugs by online pharmacies are projected to expand over the coming years. Patients can benefit greatly from the availability and convenience of online pharmacies. The number of people who buy drugs from online pharmacies is rising quickly alongside the expansion of internet access. For example, in 2020, there was a 45 percent rise from the year before in the number of products sold through internet pharmacies in Great Britain.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
In terms of revenue, North America accounted for more than 35.0% of the demand for inhalation and nasal spray generic drugs in 2021. The key elements fueling the regional expansion are the introduction of new goods, acquisitions, collaborations, and the rising incidence of chronic respiratory disorders. Statistics from the Centers for Disease Control and Prevention (CDC) show that 57 males per 100,000 and 40.5 women per 100,000 had COPD in the United States. The introduction of low-cost generic nasal sprays is anticipated to boost the industry. In the United States, for instance, Sandoz introduced a generic version of Narcan (naloxone HCl) Nasal Spray in December 2021. This spray is used to reverse the effects of an opioid overdose.
Over the course of the forecast period, the Europe inhalation and nasal spray generic drugs market is expected to expand at a CAGR of 8.1%.
In the countries of the region, cigarette consumption is incredibly high. Tobacco consumption is highest in the WHO European Region, with an estimated 209 million individuals smoking (or 29%). Furthermore, Europe has the highest smoking rate among women, with 74 million of them lighting up every day. The prevalence of smoking varies considerably between geographic regions. Tobacco use is a major contributor to health inequalities and a leading cause of preventable death and disability in the area.
In 2021, Germany market-led Europe's inhalation and nasal spray generic drugs market by country, and it's expected to maintain its dominance through 2028 when it's expected to be worth $1,998.9 million. A compound annual growth rate (CAGR) of 7.2% was predicted for the UK market. In addition, the market in France is growing at a CAGR of 8.9%.
Non-communicable diseases (NCDs) are rapidly becoming more of a problem in India than communicable diseases, including tuberculosis (TB), HIV, and water- and vector-borne illnesses. Cancer, chronic respiratory problems, and cardiovascular disease are just a few of the non-communicable diseases that account for nearly 60% of deaths in the country, as reported by the Ministry of Health and Family Welfare. The years of potential productivity lost due to NCDs are substantial. Deaths from preventable causes, such as heart disease, stroke, and respiratory illness, are also projected to increase over time, leading to greater financial losses.
In 2022, Japan was the largest country inhalation and nasal spray generic drugs market in the Asia Pacific region, and this trend is projected to continue through 2033. A compound annual growth rate (CAGR) of 8.3% is expected in the Japanese market. The market in India, meanwhile, is growing at a CAGR of 9.6 percent throughout the forecast period.
The growth of the region is attributed to the strategic partnerships to manufacture generic products in the region. For instance, in August 2021, CDMO Bora Pharmaceuticals Laboratories Inc. partnered with Kyowa Pharmaceuticals Industry Co. Ltd. to manufacture generic products, including nasal sprays, in Japan. This contract strengthens and increases the visibility of the country's pharmaceutical capabilities.
New Entrants to Foster Innovation in the Global Market
The startups in the inhalation and nasal spray generic drugs market are adding a new edge to the properties of excavators by curating innovations beyond the imagination. They are continually upgrading the Inhalation and Nasal Spray Generic Drugs with advanced technology, and manufacturers and sellers are continuously attempting to reduce costs for greater accessibility to the market share. Startup firms are triggering the expansion of the inhalation and nasal spray generic drugs market with their unique attempts.
Top startups operating in the inhalation and nasal spray generic drugs market are:
| Name | Description |
|---|---|
| QNASL | For those suffering from seasonal allergies, QNASL has created a nasal spray to help. A waterless mist (nasal aerosol), QNASL (beclomethasone dipropionate) is used once daily to treat nasal allergy symptoms such as congestion, sneezing, and an itchy, runny nose. |
| Trillium Health Care Products | Drug creator with a wide range of therapeutic targets. Over-the-counter (OTC) and prescription (RX) gastrointestinal treatments, cough, cold, and flu medication, antiseptic ointments, suppositories, nasal sprays, and allergy relief, analgesics, sleep aids, and other life science products are developed by the company. |
Major companies like Cipla Inc., Teva Pharmaceuticals, and Viatris Inc. are investing heavily in research and development, as well as product launches of brand-new products. There has been a rise in the number of generic inhalers and nasal sprays approved for the treatment of respiratory illnesses such as asthma, COPD, and allergic rhinitis, and this is expected to continue driving demand in the market. To give just one example, in March 2022, the FDA approved the ANDA for inhalation aerosol Breyna, a generic form of Symbicort intended for patients with asthma and COPD. This product is manufactured by Mylan Pharmaceuticals, a subsidiary of Viatris Inc. With this green light, the business can move on with plans to introduce Breyna in 2022.
Market leaders in Inhalation and Nasal Spray Generic Drugs worldwide include:
The growth outlook for the inhalation and nasal spray generic drugs market is predicted to advance at a CAGR of 8.96% from 2022 to 2032.
The North American region is anticipated to lead the inhalation and nasal spray generic drugs market during the forecast period.
The market valuation of the inhalation and nasal spray generic drugs market stands at US$ 20.78 Billion in 2023.
The inhalation and nasal spray generic drugs market are likely to hold a valuation of US$ 49.01 Billion by 2033.
1. Executive Summary | Inhalation And Nasal Spray Generic Drugs Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Inhalation And Nasal Spray Generic Drugs Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021 4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Inhalation And Nasal Spray Generic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Class, 2017 to 2021 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Class, 2022 to 2032 5.3.1. Bronchodilators 5.3.2. Combination Drugs 5.3.3. Corticosteroids 5.3.4. Decongestant Sprays 5.3.5. Antihistamines 5.3.6. Others 5.4. Y-o-Y Growth Trend Analysis By Class, 2017 to 2021 5.5. Absolute $ Opportunity Analysis By Class, 2022 to 2032 6. Global Inhalation And Nasal Spray Generic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Indication 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2017 to 2021 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2022 to 2032 6.3.1. Asthma 6.3.2. Chronic Obstructive Pulmonary Disease (COPD) 6.3.3. Allergic Rhinitis 6.3.4. Others 6.4. Y-o-Y Growth Trend Analysis By Indication, 2017 to 2021 6.5. Absolute $ Opportunity Analysis By Indication, 2022 to 2032 7. Global Inhalation And Nasal Spray Generic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Patient Demographics 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Patient Demographics, 2017 to 2021 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Patient Demographics, 2022 to 2032 7.3.1. Adult Patient 7.3.2. Pediatric Patient 7.3.3. Geriatric Patient 7.4. Y-o-Y Growth Trend Analysis By Patient Demographics, 2017 to 2021 7.5. Absolute $ Opportunity Analysis By Patient Demographics, 2022 to 2032 8. Global Inhalation And Nasal Spray Generic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End-user 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By End-user, 2017 to 2021 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-user, 2022 to 2032 8.3.1. Homecare 8.3.2. Hospitals 8.3.3. Others 8.4. Y-o-Y Growth Trend Analysis By End-user, 2017 to 2021 8.5. Absolute $ Opportunity Analysis By End-user, 2022 to 2032 9. Global Inhalation And Nasal Spray Generic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Distribution Channel 9.1. Introduction / Key Findings 9.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2017 to 2021 9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2022 to 2032 9.3.1. Retail Pharmacies 9.3.2. Hospitals Pharmacies 9.3.3. Online Pharmacies 9.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017 to 2021 9.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022 to 2032 10. Global Inhalation And Nasal Spray Generic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 10.1. Introduction 10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021 10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. South Asia 10.3.5. East Asia 10.3.6. Oceania 10.3.7. Middle East & Africa (MEA) 10.4. Market Attractiveness Analysis By Region 11. North America Inhalation And Nasal Spray Generic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. The US 11.2.1.2. Canada 11.2.2. By Class 11.2.3. By Indication 11.2.4. By Patient Demographics 11.2.5. By End-user 11.2.6. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Class 11.3.3. By Indication 11.3.4. By Patient Demographics 11.3.5. By End-user 11.3.6. By Distribution Channel 11.4. Key Takeaways 12. Latin America Inhalation And Nasal Spray Generic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. Brazil 12.2.1.2. Mexico 12.2.1.3. Rest of Latin America 12.2.2. By Class 12.2.3. By Indication 12.2.4. By Patient Demographics 12.2.5. By End-user 12.2.6. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Class 12.3.3. By Indication 12.3.4. By Patient Demographics 12.3.5. By End-user 12.3.6. By Distribution Channel 12.4. Key Takeaways 13. Europe Inhalation And Nasal Spray Generic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 13.2.1. By Country 13.2.1.1. Germany 13.2.1.2. The UK 13.2.1.3. France 13.2.1.4. Spain 13.2.1.5. Italy 13.2.1.6. Rest of Europe 13.2.2. By Class 13.2.3. By Indication 13.2.4. By Patient Demographics 13.2.5. By End-user 13.2.6. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Class 13.3.3. By Indication 13.3.4. By Patient Demographics 13.3.5. By End-user 13.3.6. By Distribution Channel 13.4. Key Takeaways 14. South Asia Inhalation And Nasal Spray Generic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Malaysia 14.2.1.3. Singapore 14.2.1.4. Thailand 14.2.1.5. Rest of South Asia 14.2.2. By Class 14.2.3. By Indication 14.2.4. By Patient Demographics 14.2.5. By End-user 14.2.6. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Class 14.3.3. By Indication 14.3.4. By Patient Demographics 14.3.5. By End-user 14.3.6. By Distribution Channel 14.4. Key Takeaways 15. East Asia Inhalation And Nasal Spray Generic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 15.2.1. By Country 15.2.1.1. China 15.2.1.2. Japan 15.2.1.3. South Korea 15.2.2. By Class 15.2.3. By Indication 15.2.4. By Patient Demographics 15.2.5. By End-user 15.2.6. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Class 15.3.3. By Indication 15.3.4. By Patient Demographics 15.3.5. By End-user 15.3.6. By Distribution Channel 15.4. Key Takeaways 16. Oceania Inhalation And Nasal Spray Generic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 16.2.1. By Country 16.2.1.1. Australia 16.2.1.2. New Zealand 16.2.2. By Class 16.2.3. By Indication 16.2.4. By Patient Demographics 16.2.5. By End-user 16.2.6. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Class 16.3.3. By Indication 16.3.4. By Patient Demographics 16.3.5. By End-user 16.3.6. By Distribution Channel 16.4. Key Takeaways 17. MEA Inhalation And Nasal Spray Generic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 17.2.1. By Country 17.2.1.1. GCC Countries 17.2.1.2. South Africa 17.2.1.3. Israel 17.2.1.4. Rest of MEA 17.2.2. By Class 17.2.3. By Indication 17.2.4. By Patient Demographics 17.2.5. By End-user 17.2.6. By Distribution Channel 17.3. Market Attractiveness Analysis 17.3.1. By Country 17.3.2. By Class 17.3.3. By Indication 17.3.4. By Patient Demographics 17.3.5. By End-user 17.3.6. By Distribution Channel 17.4. Key Takeaways 18. Key Countries Inhalation And Nasal Spray Generic Drugs Market Analysis 18.1. The US 18.1.1. Pricing Analysis 18.1.2. Market Share Analysis, 2021 18.1.2.1. By Class 18.1.2.2. By Indication 18.1.2.3. By Patient Demographics 18.1.2.4. By End-user 18.1.2.5. By Distribution Channel 18.2. Canada 18.2.1. Pricing Analysis 18.2.2. Market Share Analysis, 2021 18.2.2.1. By Class 18.2.2.2. By Indication 18.2.2.3. By Patient Demographics 18.2.2.4. By End-user 18.2.2.5. By Distribution Channel 18.3. Brazil 18.3.1. Pricing Analysis 18.3.2. Market Share Analysis, 2021 18.3.2.1. By Class 18.3.2.2. By Indication 18.3.2.3. By Patient Demographics 18.3.2.4. By End-user 18.3.2.5. By Distribution Channel 18.4. Mexico 18.4.1. Pricing Analysis 18.4.2. Market Share Analysis, 2021 18.4.2.1. By Class 18.4.2.2. By Indication 18.4.2.3. By Patient Demographics 18.4.2.4. By End-user 18.4.2.5. By Distribution Channel 18.5. Germany 18.5.1. Pricing Analysis 18.5.2. Market Share Analysis, 2021 18.5.2.1. By Class 18.5.2.2. By Indication 18.5.2.3. By Patient Demographics 18.5.2.4. By End-user 18.5.2.5. By Distribution Channel 18.6. The UK 18.6.1. Pricing Analysis 18.6.2. Market Share Analysis, 2021 18.6.2.1. By Class 18.6.2.2. By Indication 18.6.2.3. By Patient Demographics 18.6.2.4. By End-user 18.6.2.5. By Distribution Channel 18.7. France 18.7.1. Pricing Analysis 18.7.2. Market Share Analysis, 2021 18.7.2.1. By Class 18.7.2.2. By Indication 18.7.2.3. By Patient Demographics 18.7.2.4. By End-user 18.7.2.5. By Distribution Channel 18.8. Spain 18.8.1. Pricing Analysis 18.8.2. Market Share Analysis, 2021 18.8.2.1. By Class 18.8.2.2. By Indication 18.8.2.3. By Patient Demographics 18.8.2.4. By End-user 18.8.2.5. By Distribution Channel 18.9. Italy 18.9.1. Pricing Analysis 18.9.2. Market Share Analysis, 2021 18.9.2.1. By Class 18.9.2.2. By Indication 18.9.2.3. By Patient Demographics 18.9.2.4. By End-user 18.9.2.5. By Distribution Channel 18.10. India 18.10.1. Pricing Analysis 18.10.2. Market Share Analysis, 2021 18.10.2.1. By Class 18.10.2.2. By Indication 18.10.2.3. By Patient Demographics 18.10.2.4. By End-user 18.10.2.5. By Distribution Channel 18.11. Malaysia 18.11.1. Pricing Analysis 18.11.2. Market Share Analysis, 2021 18.11.2.1. By Class 18.11.2.2. By Indication 18.11.2.3. By Patient Demographics 18.11.2.4. By End-user 18.11.2.5. By Distribution Channel 18.12. Singapore 18.12.1. Pricing Analysis 18.12.2. Market Share Analysis, 2021 18.12.2.1. By Class 18.12.2.2. By Indication 18.12.2.3. By Patient Demographics 18.12.2.4. By End-user 18.12.2.5. By Distribution Channel 18.13. Thailand 18.13.1. Pricing Analysis 18.13.2. Market Share Analysis, 2021 18.13.2.1. By Class 18.13.2.2. By Indication 18.13.2.3. By Patient Demographics 18.13.2.4. By End-user 18.13.2.5. By Distribution Channel 18.14. China 18.14.1. Pricing Analysis 18.14.2. Market Share Analysis, 2021 18.14.2.1. By Class 18.14.2.2. By Indication 18.14.2.3. By Patient Demographics 18.14.2.4. By End-user 18.14.2.5. By Distribution Channel 18.15. Japan 18.15.1. Pricing Analysis 18.15.2. Market Share Analysis, 2021 18.15.2.1. By Class 18.15.2.2. By Indication 18.15.2.3. By Patient Demographics 18.15.2.4. By End-user 18.15.2.5. By Distribution Channel 18.16. South Korea 18.16.1. Pricing Analysis 18.16.2. Market Share Analysis, 2021 18.16.2.1. By Class 18.16.2.2. By Indication 18.16.2.3. By Patient Demographics 18.16.2.4. By End-user 18.16.2.5. By Distribution Channel 18.17. Australia 18.17.1. Pricing Analysis 18.17.2. Market Share Analysis, 2021 18.17.2.1. By Class 18.17.2.2. By Indication 18.17.2.3. By Patient Demographics 18.17.2.4. By End-user 18.17.2.5. By Distribution Channel 18.18. New Zealand 18.18.1. Pricing Analysis 18.18.2. Market Share Analysis, 2021 18.18.2.1. By Class 18.18.2.2. By Indication 18.18.2.3. By Patient Demographics 18.18.2.4. By End-user 18.18.2.5. By Distribution Channel 18.19. GCC Countries 18.19.1. Pricing Analysis 18.19.2. Market Share Analysis, 2021 18.19.2.1. By Class 18.19.2.2. By Indication 18.19.2.3. By Patient Demographics 18.19.2.4. By End-user 18.19.2.5. By Distribution Channel 18.20. South Africa 18.20.1. Pricing Analysis 18.20.2. Market Share Analysis, 2021 18.20.2.1. By Class 18.20.2.2. By Indication 18.20.2.3. By Patient Demographics 18.20.2.4. By End-user 18.20.2.5. By Distribution Channel 18.21. Israel 18.21.1. Pricing Analysis 18.21.2. Market Share Analysis, 2021 18.21.2.1. By Class 18.21.2.2. By Indication 18.21.2.3. By Patient Demographics 18.21.2.4. By End-user 18.21.2.5. By Distribution Channel 19. Market Structure Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Market Share Analysis of Top Players 19.3.1. By Regional 19.3.2. By Class 19.3.3. By Indication 19.3.4. By Patient Demographics 19.3.5. By End-user 19.3.6. By Distribution Channel 20. Competition Analysis 20.1. Competition Deep Dive 20.1.1. Teva Pharmaceuticals Industries Ltd. 20.1.1.1. Overview 20.1.1.2. Product Portfolio 20.1.1.3. Profitability by Market Segments 20.1.1.4. Sales Footprint 20.1.1.5. Strategy Overview 20.1.1.5.1. Marketing Strategy 20.1.2. Mylan N.V. 20.1.2.1. Overview 20.1.2.2. Product Portfolio 20.1.2.3. Profitability by Market Segments 20.1.2.4. Sales Footprint 20.1.2.5. Strategy Overview 20.1.2.5.1. Marketing Strategy 20.1.3. Akorn, Operating Company LLC 20.1.3.1. Overview 20.1.3.2. Product Portfolio 20.1.3.3. Profitability by Market Segments 20.1.3.4. Sales Footprint 20.1.3.5. Strategy Overview 20.1.3.5.1. Marketing Strategy 20.1.4. Cipla Inc. 20.1.4.1. Overview 20.1.4.2. Product Portfolio 20.1.4.3. Profitability by Market Segments 20.1.4.4. Sales Footprint 20.1.4.5. Strategy Overview 20.1.4.5.1. Marketing Strategy 20.1.5. Sandoz International GmBH (Novartis AG) 20.1.5.1. Overview 20.1.5.2. Product Portfolio 20.1.5.3. Profitability by Market Segments 20.1.5.4. Sales Footprint 20.1.5.5. Strategy Overview 20.1.5.5.1. Marketing Strategy 20.1.6. Apotex Inc. 20.1.6.1. Overview 20.1.6.2. Product Portfolio 20.1.6.3. Profitability by Market Segments 20.1.6.4. Sales Footprint 20.1.6.5. Strategy Overview 20.1.6.5.1. Marketing Strategy 20.1.7. Hikma Pharmaceuticals PLC 20.1.7.1. Overview 20.1.7.2. Product Portfolio 20.1.7.3. Profitability by Market Segments 20.1.7.4. Sales Footprint 20.1.7.5. Strategy Overview 20.1.7.5.1. Marketing Strategy 20.1.8. Sun Pharmaceuticals Industries Ltd. 20.1.8.1. Overview 20.1.8.2. Product Portfolio 20.1.8.3. Profitability by Market Segments 20.1.8.4. Sales Footprint 20.1.8.5. Strategy Overview 20.1.8.5.1. Marketing Strategy 20.1.9. Beximco Pharmaceuticals Ltd. 20.1.9.1. Overview 20.1.9.2. Product Portfolio 20.1.9.3. Profitability by Market Segments 20.1.9.4. Sales Footprint 20.1.9.5. Strategy Overview 20.1.9.5.1. Marketing Strategy 20.1.10. Nephron Pharmaceuticals Corporation 20.1.10.1. Overview 20.1.10.2. Product Portfolio 20.1.10.3. Profitability by Market Segments 20.1.10.4. Sales Footprint 20.1.10.5. Strategy Overview 20.1.10.5.1. Marketing Strategy 21. Assumptions & Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Inhalation And Nasal Spray Generic Drugs Market
